Skip to main content

Displaying 2481 - 2500 of 4526

Schering-Plough Corporation, , In the Matter of

The Commission challenged Schering-Plough’s proposed $41.4 billion acquisition of Merck & Co., and required divestitures to preserve competition in markets for human and animal pharmaceuticals. The proposed consent order requires that Merck sell its interest in Merial Limited, an animal health joint venture with Sanofi-Aventis S.A., and that Schering-Plough sell its assets related to significant drugs for nausea and vomiting in humans.

Type of Action
Administrative
Last Updated
FTC Matter/File Number
091 0075
Docket Number
C-4268